Update cookies preferences

Free Download

Graphical Abstract

Advancing the research on management of global airway disease: insights from a post hoc analysis

Volume: 63 - Issue: 1

First page: 1 - Last page: 1

S. Toppila-Salmi

DOI: 10.4193/Rhin25.901

Chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, and non-steroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD) frequently coexist, forming a complex multimorbid condition often referred to as “global airway disease.” This concept reflects shared pathophysiological mechanisms of eosinophilic inflammation and underscores the need for integrated treatment strategies targeting both upper and lower airway manifestations (1). The burden of severe CRSwNP, asthma, and N-ERD is substantial, particularly in terms of reduced quality of life, recurrent exacerbations, revision endoscopic sinus surgeries (ESS), and healthcare utilization (2). Biologics represent a significant advancement in the treatment of global airway diseases.

Rhinology 63-1: 1-1, 2025

To see the issue content and the abstract you do not have to login

Please login to download the full articles

If you do not have a subscription to Rhinology please consider taking one.

Click here to become a member of the European Rhinologic Society and a subscriber to the journal `RHINOLOGY`, from 2025. Subscription including membership fee: Euro 135.-